Switching to Orenitram may benefit some PAH patients on Uptravi
Switching to Orenitram, an oral formulation of treprostinil, appears safe and may benefit some patients with pulmonary arterial hypertension (PAH) who are not responding well to Uptravi (selexipag) or are experiencing side effects from such treatment. That’s according to data from a small group of 10 patients who…